Halozyme Therapeutics (HALO) Misses Q3 EPS by 3c
Get Alerts HALO Hot Sheet
Price: $40.68 -0.12%
EPS Growth %: +57.4%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
FSI, RELV, NEOM, More
EPS Growth %: +57.4%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
FSI, RELV, NEOM, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $24.01 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2 reasons why Tesla stock fell on Thursday
- P3 Health Partners Inc. (PIII) Misses Q4 EPS by 14c, reaffirms guidance
- Oxford Industries (OXM) Reports In-Line Q4 EPS, provides guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!